Literature DB >> 29907935

Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population.

Lucero Monterde-Cruz1, Eric G Ramírez-Salazar2,3, Genaro Rico-Martínez1, Luis M Linares-González1, Roberto Guzmán-González1, Ernesto Delgado-Cedillo1, Eréndira Estrada-Villaseñor1, Margarita Valdés-Flores1, Rafael Velázquez-Cruz4, Alberto Hidalgo-Bravo5.   

Abstract

Osteosarcoma is the most common malignant bone neoplasia affecting individuals in the second decade of life. The survival rate has not been improved during the last 25 years, in part because of the lack of specific markers. The microRNAs have been identified as important regulators of gene expression, experimental evidence suggests these molecules as key players in cancer development and progression. To identify miRNAs differentially expressed in serum from patients with osteosarcoma compared to healthy donors in Mexican population. Fifteen osteosarcoma patients and fifteen age and sex matched healthy individuals were recruited. Two pools of total RNA extracted from serum per study group were prepared and the miRNA expression profiles were analyzed through TaqMan Low Density Arrays. Validation was carried out through RT-qPCR using individual TaqMan assays for those miRNAs differentially expressed. Fifteen miRNAs were differentially expressed in osteosarcoma patients compared to healthy controls. Overexpression of miR-215-5p and miR-642a-5p was confirmed by validation through RT-qPCR. The expression analysis of miRNAs from serum in osteosarcoma patients revealed differential expression of miR-215-5p and miR-642a-5p. Both microRNAs are potential markers for osteosarcoma diagnosis.

Entities:  

Keywords:  Biomarkers; Osteosarcoma; Serum; Target genes; microRNAs

Mesh:

Substances:

Year:  2018        PMID: 29907935     DOI: 10.1007/s13577-018-0214-1

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  25 in total

1.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P C W Hogendoorn; N Athanasou; S Bielack; E De Alava; A P Dei Tos; S Ferrari; H Gelderblom; R Grimer; K Sundby Hall; B Hassan; P C W Hogendoorn; H Jurgens; M Paulussen; L Rozeman; A H M Taminiau; J Whelan; D Vanel
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

Review 3.  Circulating cell-free microRNAs as clinical cancer biomarkers.

Authors:  Virginie Armand-Labit; Anne Pradines
Journal:  Biomol Concepts       Date:  2017-05-24

Review 4.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

5.  MiR-215 modulates gastric cancer cell proliferation by targeting RB1.

Authors:  Yujie Deng; Zhenxia Huang; Yanjun Xu; Juan Jin; Wei Zhuo; Cheng Zhang; Xuting Zhang; Minhong Shen; Xiaoyi Yan; Liangjing Wang; Xiaojia Wang; Yibin Kang; Jianmin Si; Tianhua Zhou
Journal:  Cancer Lett       Date:  2013-08-24       Impact factor: 8.679

6.  MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma.

Authors:  Yuzhen Wei; Jianjing Sun; Xingang Li
Journal:  Biotechnol Lett       Date:  2016-11-11       Impact factor: 2.716

Review 7.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

8.  Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma.

Authors:  Feng Lian; Yong Cui; Chenliang Zhou; Kewei Gao; Liwen Wu
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program.

Authors:  Roberto Rivera-Luna; Jaime Shalkow-Klincovstein; Liliana Velasco-Hidalgo; Rocio Cárdenas-Cardós; Marta Zapata-Tarrés; Alberto Olaya-Vargas; Marco R Aguilar-Ortiz; Eduardo Altamirano-Alvarez; Cecilia Correa-Gonzalez; Fernando Sánchez-Zubieta; Francisco Pantoja-Guillen
Journal:  BMC Cancer       Date:  2014-10-29       Impact factor: 4.430

10.  miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.

Authors:  Iver Nordentoft; Karin Birkenkamp-Demtroder; Mads Agerbæk; Dan Theodorescu; Marie Stampe Ostenfeld; Arndt Hartmann; Michael Borre; Torben F Ørntoft; Lars Dyrskjøt
Journal:  BMC Med Genomics       Date:  2012-09-06       Impact factor: 3.063

View more
  14 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

4.  miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN.

Authors:  Ming He; Peng Shen; Chuang Qiu; Jiashi Wang
Journal:  Aging (Albany NY)       Date:  2019-08-14       Impact factor: 5.682

Review 5.  Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.

Authors:  Barbara Pardini; Alexandru Anton Sabo; Giovanni Birolo; George Adrian Calin
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

6.  MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1.

Authors:  Xiaoguang Wang; Zhengwei Song; Biwen Hu; Zhenwei Chen; Fei Chen; Chenxi Cao
Journal:  Oncol Rep       Date:  2020-12-18       Impact factor: 3.906

7.  MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients.

Authors:  Lin Jin; Yue Luo; Ying-Chun Zhao; Hai Tao
Journal:  Cancer Manag Res       Date:  2021-01-27       Impact factor: 3.989

8.  Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.

Authors:  Imteyaz Ahmad Khan; Safoora Rashid; Nidhi Singh; Sumaira Rashid; Vishwajeet Singh; Deepak Gunjan; Prasenjit Das; Nihar Ranjan Dash; Ravindra Mohan Pandey; Shyam Singh Chauhan; Surabhi Gupta; Anoop Saraya
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

9.  Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.

Authors:  Zhen-Bin Diao; Tian-Xiao Sun; Yi Zong; Bo-Chuan Lin; Yuan-Sheng Xia
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

10.  Signatures of circulating microRNA in four sarcoma subtypes.

Authors:  Hanna Kosela-Paterczyk; Agnieszka Paziewska; Maria Kulecka; Aneta Balabas; Anna Kluska; Michalina Dabrowska; Magdalena Piatkowska; Natalia Zeber-Lubecka; Filip Ambrozkiewicz; Jakub Karczmarski; Michal Mikula; Piotr Rutkowski; Jerzy Ostrowski
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.